Our Bone and Soft Tissue Tumor Program combines the expertise of clinicians at both Dana-Farber and Boston Children's Hospital to provide comprehensive care for children and teens with benign or malignant bone and soft tissue tumors. Our care team consists of specialists who work closely together to design the best possible treatment plan for your child.
Bone and soft tissue tumors form in the body’s connective tissue, which includes bone, cartilage, blood and fat. Some, but not all, of these tumors are malignant, meaning they have the ability to spread to other parts of the body. Malignant tumors are often called sarcomas.
Our Bone and Soft Tissue Program offers a multidisciplinary treatment approach to care for your child.
The Bone and Soft Tissue Tumor Program treats children with the following benign and malignant conditions:
Our oncologic and orthopedic surgeons are highly experienced in bone and soft tissue operations. If you are considering where to get treatment for your child, it’s important to know that outcomes are better when treatment is provided by surgeons with expertise in treating these conditions.
The Bone and Soft Tissue Tumor Program was one of the first in the country to use adjuvant chemotherapy and perform limb salvage surgery for patients with osteosarcoma. Your child’s care team consists of specialists who work closely together to design the best possible treatment plan.
The members of the care team include:
At Dana-Farber/Boston Children's, we consider you and your child integral parts of the care team and not simply recipients of care. Your team will work together with you to customize a treatment plan that takes the needs of your child and your family into account.
Our staff of compassionate and experienced pediatric specialists includes oncologists, orthopedic surgeons, radiation oncologists, radiologists, pathologists, and pediatric nurses.
Our physicians are focused on family-centered care: From your first visit, you’ll work with a team of professionals who are committed to supporting all of your family’s physical and psychosocial needs.
The main objective of our research program is to improve the understanding of bone and soft tissue cancers and develop new ways to treat children with these conditions. We participate in internal research initiatives as well as those directed by the Children’s Oncology Group, an international research collaboration.
Dana-Farber/Boston Children’s is a world leader in opening new avenues of translational research, which brings laboratory advances to the bedside and doctor's office as quickly as possible.
All senior medical staff of the Bone and Soft Tissue Tumors Program participate in clinical research activities. Our program director, Carlos Rodriguez-Galindo, MD, is also the co-director of our new Clinical and Translational Investigation Program, which aims to dramatically improve translational research in pediatric hematology and oncology.
Clinical trials evaluate the effectiveness of new cancer treatments. The Bone and Soft Tissue Program participates in several multi-center national clinical trials.
In addition to a wide variety of clinical trials, Dana-Farber/Boston Children's also conducts extensive laboratory research to identify new treatments and improve therapies for bone and soft tissue tumors.
In the past 20 years, there has only been one new treatment introduced for young patients with osteosarcoma. In addition, children who relapse or who develop lung metastases have fewer effective treatment options. To remedy this, Katherine Janeway, MD, a pediatric oncologist and researcher, is conducting research to identify new treatments for osteosarcoma.
Dana-Farber/Boston Children's is the New England Phase I Center of the Children's Oncology Group. If your child has progressive or recurrent bone or soft tissue tumor, he or she may be eligible for a number of experimental therapies available through these groups, or through one of our independent clinical investigators.
The Children's Oncology Group is a consortium of cancer treatment centers across the United States, Canada, and other countries, that conduct studies of Ewing sarcoma, osteosarcoma, rhabdomyosarcoma and other soft tissue sarcomas. Our participation in the Children’s Oncology Group gives children with bone and soft tissue tumors unparalleled access to the newest clinical trials.
The long-term outcome for children with soft tissue and bone tumors is improving. How well each child does depends on a variety of factors, including the type of tumor and whether the disease has spread (metastasized) by the time of diagnosis. Our research continues to help us understand the causes of cancer so we can develop more targeted, effective therapies.
The David B. Perini Quality of Life Clinic helps survivors of childhood cancer of all ages address the medical, psychological and social consequences of their diagnosis and treatment. Childhood cancer survivors who have been out of active treatment for two years are invited to visit our clinic for follow-up care.
Referring physicians: 617-632-5508 or 1-888-Pedi-Onc (733-4662)
We understand a cancer diagnosis is extremely difficult to cope with. We are available to offer a consultation or second opinion for your child.
If your child has a diagnosis of bone or soft tissue cancer, please contact our program at 888-PEDI-ONC (888-733-4662).
To help us conduct a precise evaluation, it’s important we receive a full summary of your child's initial diagnosis. This includes any laboratory or pathology reports, any x-ray, radiographic or MRI images and a list of any previous treatments your child may have received. Please have as much of the following information gathered as possible when you call or bring it with you to your appointment:
Complete clinical summary
Boston Children's Hospital300 Longwood AvenueBoston, MA 02115
Dana-Farber Cancer Institute450 Brookline Ave.Boston, MA 02215
Browse clinical trials
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free:
(866) 408-DFCI (3324)